• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Onconova Therapeutics Inc. (Amendment)

    2/14/22 3:20:33 PM ET
    $ONTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONTX alert in real time by email
    SC 13G/A 1 tm226115d9_sc13ga.htm SC 13G/A

     

    CUSIP No:     68232V801

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Onconova Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    68232V801
    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:     68232V801

     

    (1) NAMES OF REPORTING PERSONS
       
      CVI Investments, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
        (b) ¨
       
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands

     
    NUMBER OF (5) SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY (6) SHARED VOTING POWER **
       
    OWNED BY 0
       
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING   0
       
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
       
      0

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      0
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨ 
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:     68232V801

     

    (1) NAMES OF REPORTING PERSONS
       
      Heights Capital Management, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
        (b) ¨
       
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

     
    NUMBER OF (5) SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY (6) SHARED VOTING POWER **
       
    OWNED BY 0
       
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING   0
       
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
       
      0

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      0
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨ 
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:     68232V801

      

    Item 1.

     

    (a) Name of Issuer

     

    Onconova Therapeutics, Inc. (the “Company”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    12 Penns Trail, Newtown, PA 18940

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.01 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

      

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.01 par value per share

     

    Item 2(e) CUSIP Number

     

    68232V801

     

     

     

     

    CUSIP No:     68232V801

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
     
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

       

     

     

    CUSIP No:     68232V801

     

    Item 7.        Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No:     68232V801

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated:   February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which was previously filed Name: Brian Sopinsky
        Title: Secretary
         
    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary      

     

     

     

     

    CUSIP No:     68232V801

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

    Get the next $ONTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONTX

    DatePrice TargetRatingAnalyst
    3/1/2022$7.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ONTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/12/24 4:11:22 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/11/24 5:41:38 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redfield Robert was granted 97,500 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:07:09 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    SEC Filings

    See more
    • SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)

      10-K/A - Traws Pharma, Inc. (0001130598) (Filer)

      4/29/24 4:06:03 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Onconova Therapeutics Inc.

      D - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:15:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Onconova Therapeutics Inc.

      DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:09:29 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Onconova Therapeutics with a new price target

      Ladenburg Thalmann initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $7.00

      3/1/22 7:21:18 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Onconova Therapeutics with a new price target

      Guggenheim initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $4.00

      5/18/21 6:31:16 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Financials

    Live finance-specific insights

    See more

    $ONTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ONTX
    Leadership Updates

    Live Leadership Updates

    See more

    $ONTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

      Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results a

      11/14/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

      NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic or(646

      11/7/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

      Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial results a

      8/10/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma Announces New Employee Inducement Grants

      NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar

      4/2/24 7:15:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

      Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo

      4/2/24 7:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

      NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. "The ability to impact multiple targets is an important characteristic of Onconova's two lead clinical programs, rigosertib and naraz

      3/8/24 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Expands Leadership Team with Two Key Appointments

      Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

      10/24/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

      NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company's Board of Directors. "It is my pleasure to welcome Peter and Trafford to our Board," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "Their track record of successfully building and leading teams tasked with the discovery, development, and delivery of novel therapies is impressive. I look forward to benefiti

      12/19/22 4:05:23 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

      NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. "Adar's deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our team at Onconova," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "We are thrilled to have her join us and look forward to benefitting from her insights. Her str

      12/13/21 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconova Therapeutics Inc.

      SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

      4/8/24 9:37:11 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Onconova Therapeutics Inc. (Amendment)

      SC 13G/A - Onconova Therapeutics, Inc. (0001130598) (Subject)

      2/14/22 3:20:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Onconova Therapeutics, Inc.

      SC 13G - Onconova Therapeutics, Inc. (0001130598) (Subject)

      10/1/21 11:01:51 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care